Chapter 13 – Rabies Vaccines

[1]  Maolin Zhang,et al.  Oral immunisation of mice with a recombinant rabies virus vaccine incorporating the heat-labile enterotoxin B subunit of Escherichia coli in an attenuated Salmonella strain. , 2012, Research in veterinary science.

[2]  A. Ertel,et al.  Postexposure Treatment with the Live-Attenuated Rabies Virus (RV) Vaccine TriGAS Triggers the Clearance of Wild-Type RV from the Central Nervous System (CNS) through the Rapid Induction of Genes Relevant to Adaptive Immunity in CNS Tissues , 2012, Journal of Virology.

[3]  A. Kamen,et al.  Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). , 2012, Vaccine.

[4]  V. Dato,et al.  National surveillance for human and pet contact with oral rabies vaccine baits, 2001-2009. , 2012, Journal of the American Veterinary Medical Association.

[5]  D. Slate,et al.  COMPARING ONRAB® AND RABORAL V-RG® ORAL RABIES VACCINE FIELD PERFORMANCE IN RACCOONS AND STRIPED SKUNKS, NEW BRUNSWICK, CANADA, AND MAINE, USA , 2012, Journal of wildlife diseases.

[6]  E. Kamphuis,et al.  Potency testing of veterinary vaccines: the way from in vivo to in vitro. , 2012, Biologicals : journal of the International Association of Biological Standardization.

[7]  Udo Reichl,et al.  Downstream processing of cell culture-derived virus particles , 2011, Expert review of vaccines.

[8]  Z. Bu,et al.  Generation of a recombinant rabies Flury LEP virus carrying an additional G gene creates an improved seed virus for inactivated vaccine production , 2011, Virology Journal.

[9]  S. Finke,et al.  Immunogenicity Studies in Carnivores Using a Rabies Virus Construct with a Site-Directed Deletion in the Phosphoprotein , 2011, Advances in preventive medicine.

[10]  Catherine M. Brown,et al.  Compendium of animal rabies prevention and control, 2011. , 2011, Journal of the American Veterinary Medical Association.

[11]  P. Jahrling,et al.  Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses , 2011, Journal of Virology.

[12]  E. Montomoli,et al.  Current adjuvants and new perspectives in vaccine formulation , 2011, Expert review of vaccines.

[13]  M. Schnell,et al.  Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. , 2011, Vaccine.

[14]  C. Rupprecht,et al.  Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies. , 2011, Vaccine.

[15]  Hualan Chen,et al.  Newcastle Disease Virus-Vectored Rabies Vaccine Is Safe, Highly Immunogenic, and Provides Long-Lasting Protection in Dogs and Cats , 2011, Journal of Virology.

[16]  Q. Tang,et al.  Development of recombinant rabies viruses vectors with Gaussia luciferase reporter based on Chinese vaccine strain CTN181 , 2011, Virus Research.

[17]  C. Wirblich,et al.  Rabies Virus as a Research Tool and Viral Vaccine Vector , 2011, Advances in Virus Research.

[18]  Weiqi Pan,et al.  Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. , 2011, Vaccine.

[19]  P. Bachmann,et al.  High-Density Baiting with ONRAB® Rabies Vaccine Baits to Control Arctic-Variant Rabies in Striped Skunks in Ontario, Canada , 2011, Journal of wildlife diseases.

[20]  M. Shokrgozar,et al.  High vero cell density and rabies virus proliferation on fibracel disks versus cytodex-1 in spinner flask. , 2011, Pakistan journal of biological sciences : PJBS.

[21]  S. Cleaveland,et al.  Evaluation of Cost-Effective Strategies for Rabies Post-Exposure Vaccination in Low-Income Countries , 2011, PLoS neglected tropical diseases.

[22]  C. Jallet,et al.  Canine adenoviruses elicit both humoral and cell-mediated immune responses against rabies following immunisation of sheep. , 2011, Vaccine.

[23]  M. Schnell,et al.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. , 2010, Vaccine.

[24]  Hualei Wang,et al.  Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to Vaccination , 2010, Journal of Virology.

[25]  P. Kaleebu,et al.  Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae , 2010, Journal of Virology.

[26]  Yongli Yu,et al.  A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use. , 2010, Vaccine.

[27]  M. Delepierre,et al.  Attenuation of Rabies Virulence: Takeover by the Cytoplasmic Domain of Its Envelope Protein , 2010, Science Signaling.

[28]  M. Schnell,et al.  Characterization of a Single-Cycle Rabies Virus-Based Vaccine Vector , 2010, Journal of Virology.

[29]  C. Wirblich,et al.  The cell biology of rabies virus: using stealth to reach the brain , 2010, Nature Reviews Microbiology.

[30]  Timothy P. Algeo,et al.  Oral Rabies Vaccination in North America: Opportunities, Complexities, and Challenges , 2009, PLoS neglected tropical diseases.

[31]  C. Rupprecht,et al.  Development of combined vaccines for rabies and immunocontraception. , 2009, Vaccine.

[32]  D. Slate,et al.  Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine. , 2009, Vaccine.

[33]  C. Rupprecht,et al.  Poxvirus-vectored vaccines for rabies--a review. , 2009, Vaccine.

[34]  S. Nadin-Davis,et al.  Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB) in target and non-target species. , 2009, Vaccine.

[35]  P. Marx,et al.  Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. , 2009, The Journal of infectious diseases.

[36]  M. Penny,et al.  Transmission dynamics and economics of rabies control in dogs and humans in an African city , 2009, Proceedings of the National Academy of Sciences.

[37]  B. Dietzschold,et al.  Immunogenicity and Safety of Recombinant Rabies Viruses Used for Oral Vaccination of Stray Dogs and Wildlife , 2009, Zoonoses and public health.

[38]  B. Dietzschold,et al.  Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus , 2009, Proceedings of the National Academy of Sciences.

[39]  L. Geue,et al.  Analysis of vaccine-virus-associated rabies cases in red foxes (Vulpes vulpes) after oral rabies vaccination campaigns in Germany and Austria , 2009, Archives of Virology.

[40]  P. Cabello,et al.  Potency evaluation of rabies vaccine for human use: the impact of the reduction in the number of animals per dilution. , 2009, Journal of virological methods.

[41]  P. Bachmann,et al.  AERIAL DISTRIBUTION OF ONRAB® BAITS AS A TACTIC TO CONTROL RABIES IN RACCOONS AND STRIPED SKUNKS IN ONTARIO, CANADA , 2009, Journal of wildlife diseases.

[42]  K. Hanschmann,et al.  The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[43]  C. Hendriksen,et al.  Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement , 2009, Expert review of vaccines.

[44]  Craig Packer,et al.  Transmission Dynamics and Prospects for the Elimination of Canine Rabies , 2009, PLoS biology.

[45]  R. Wagner,et al.  High-level expression of rabies virus glycoprotein with the RNA-based Semliki Forest Virus expression vector. , 2009, Journal of biotechnology.

[46]  G. Ma,et al.  Efficacy and safety of a live canine adenovirus-vectored rabies virus vaccine in swine. , 2008, Vaccine.

[47]  M. Echavarria.  Adenoviruses in Immunocompromised Hosts , 2008, Clinical Microbiology Reviews.

[48]  M. Schnell,et al.  Concepts in the pathogenesis of rabies. , 2008, Future virology.

[49]  R. Fayrer-Hosken.  Controlling animal populations using anti-fertility vaccines. , 2008, Reproduction in domestic animals = Zuchthygiene.

[50]  V. Martella,et al.  Canine Adenoviruses and Herpesvirus , 2008, Veterinary Clinics of North America: Small Animal Practice.

[51]  Musheng Bao,et al.  A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. , 2008, Vaccine.

[52]  A. Fooks,et al.  Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. , 2008, Vaccine.

[53]  C. Jallet,et al.  Canine adenovirus based rabies vaccines. , 2008, Developments in biologicals.

[54]  S. Nadin-Davis,et al.  ERA VACCINE-DERIVED CASES OF RABIES IN WILDLIFE AND DOMESTIC ANIMALS IN ONTARIO, CANADA, 1989–2004 , 2008, Journal of wildlife diseases.

[55]  C. Rupprecht,et al.  Glycoprotein gene relocation in rabies virus. , 2008, Virus research.

[56]  M. Schnell,et al.  The Glycoprotein and the Matrix Protein of Rabies Virus Affect Pathogenicity by Regulating Viral Replication and Facilitating Cell-to-Cell Spread , 2007, Journal of Virology.

[57]  J. Blanton,et al.  Oral vaccination of raccoons (Procyon lotor) with genetically modified rabies virus vaccines. , 2007, Vaccine.

[58]  A. Fooks,et al.  Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. , 2007, Vaccine.

[59]  J. Douglas,et al.  Adenoviral vectors for gene therapy , 2007, Molecular biotechnology.

[60]  M. Schnell,et al.  A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. , 2006, Virology.

[61]  Z. Xiang,et al.  A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  R. Pomerantz,et al.  Rabies virus glycoprotein as a carrier for anthrax protective antigen , 2006, Virology.

[63]  K. Dellagi,et al.  Immunogenicity and efficacy of an in-house developed cell-culture derived veterinarian rabies vaccine. , 2006, Vaccine.

[64]  A. Fooks,et al.  Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. , 2006, Microbes and infection.

[65]  Kenneth D. Mandl,et al.  Validation of Syndromic Surveillance for Respiratory Infections , 2006, Annals of Emergency Medicine.

[66]  V. A. Srinivasan,et al.  Validation of the inactivant binary ethylenimine for inactivating rabies virus for veterinary rabies vaccine production. , 2005, Biologicals : journal of the International Association of Biological Standardization.

[67]  H. Ertl.  Immunological insights from genetic vaccines. , 2005, Virus research.

[68]  J. Blanton,et al.  Oral vaccination of dogs with recombinant rabies virus vaccines. , 2005, Virus research.

[69]  A. Roberts,et al.  A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. , 2005, The Journal of general virology.

[70]  D. Curiel,et al.  Productive Replication of Human Adenovirus Type 5 in Canine Cells , 2005, Journal of Virology.

[71]  H. Tsujimoto,et al.  IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination , 2005, Veterinary Immunology and Immunopathology.

[72]  M. Schnell,et al.  In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. , 2004, Vaccine.

[73]  M. Aubert,et al.  Elimination of terrestrial rabies in Western European countries. , 2004, Developments in biologicals.

[74]  M. Schnell,et al.  New approaches to the prevention and eradication of rabies , 2003, Expert review of vaccines.

[75]  P. Wunderli,et al.  Effect of heterogeneity of rabies virus strain and challenge route on efficacy of inactivated rabies vaccines in mice. , 2003, American journal of veterinary research.

[76]  H. Kallel,et al.  A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-l bioreactor , 2003, Applied Microbiology and Biotechnology.

[77]  C. Langevin,et al.  Mutations Conferring Resistance to Neutralization by a Soluble Form of the Neurotrophin Receptor (p75NTR) Map outside of the Known Antigenic Sites of the Rabies Virus Glycoprotein , 2002, Journal of Virology.

[78]  J. Birch.  Suspension Culture, Animal Cells , 2002 .

[79]  S. Bressanelli,et al.  Rabies Virus Glycoprotein (RVG) Is a Trimeric Ligand for the N-terminal Cysteine-rich Domain of the Mammalian p75 Neurotrophin Receptor* , 2002, The Journal of Biological Chemistry.

[80]  D. Tang,et al.  Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein. , 2002, Veterinary Microbiology.

[81]  Z. Xiang,et al.  Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product , 2002, Journal of Virology.

[82]  J. L. Fabio,et al.  Considerations for combination vaccine development and use in the developing world. , 2001 .

[83]  T. Müller,et al.  Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. , 2001, The Journal of general virology.

[84]  M. Schnell,et al.  Genetic engineering of live rabies vaccines. , 2001, Vaccine.

[85]  R. B. Stewart,et al.  ELIMINATION OF RABIES FROM RED FOXES IN EASTERN ONTARIO , 2001, Journal of wildlife diseases.

[86]  Z. Xiang,et al.  Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. , 2000, Vaccine.

[87]  O. Danos,et al.  Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer , 2000, Journal of Virology.

[88]  D. Straughan,et al.  Validation of alternative methods for the potency testing of vaccines. , 1998, Alternatives to laboratory animals : ATLA.

[89]  C. Hanlon,et al.  FIRST NORTH AMERICAN FIELD RELEASE OF A VACCINIA-RABIES GLYCOPROTEIN RECOMBINANT VIRUS , 1998, Journal of wildlife diseases.

[90]  K. Stöhr,et al.  Progress and setbacks in the oral immunisation of foxes against rabies in Europe , 1996, Veterinary Record.

[91]  E. Paoletti,et al.  Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. , 1996, Vaccine.

[92]  W. Wold,et al.  E3 transcription unit of adenovirus. , 1995, Current topics in microbiology and immunology.

[93]  M. Corbel.  Control testing of combined vaccines: a consideration of potential problems and approaches. , 1994, Biologicals : journal of the International Association of Biological Standardization.

[94]  K. Conzelmann,et al.  Infectious rabies viruses from cloned cDNA. , 1994, The EMBO journal.

[95]  M. Artois,et al.  Oral wildlife rabies vaccination field trials in Europe, with recent emphasis on France. , 1994, Current topics in microbiology and immunology.

[96]  K. Stöhr,et al.  [Experiences with the aerial distribution of baits for the oral immunization of foxes against rabies in eastern Germany]. , 1993, DTW. Deutsche tierarztliche Wochenschrift.

[97]  R. Ruigrok,et al.  Rabies virus glycoprotein is a trimer , 1992, Virology.

[98]  C. Rupprecht,et al.  PREREQUISITES FOR ORAL IMMUNIZATION OF FREE-RANGING RACCOONS (PROCYON LOTOR) WITH A RECOMBINANT RABIES VIRUS VACCINE: STUDY SITE ECOLOGY AND BAIT SYSTEM DEVELOPMENT , 1992, Journal of wildlife diseases.

[99]  M. Kieny,et al.  Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine , 1991, Nature.

[100]  F. Graham,et al.  Manipulation of adenovirus vectors. , 1991, Methods in molecular biology.

[101]  H. Bahnemann.  Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine , 1990, Vaccine.

[102]  Grachev Vp.  World Health Organization attitude concerning the use of continuous cell lines as substrates for production of human virus vaccines. , 1990 .

[103]  M. Aubert,et al.  Effect of strain differences on the potency testing of rabies vaccines in mice. , 1989, Journal of biological standardization.

[104]  P. Pastoret,et al.  First field trial of fox vaccination against rabies using a vaccinia-rabies recombinant virus , 1988, Veterinary Record.

[105]  A. Flamand,et al.  Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence , 1988, Journal of virology.

[106]  C. Trimarchi,et al.  Comparison of sensitivity of BHK-21 and murine neuroblastoma cells in the isolation of a street strain rabies virus , 1987, Journal of clinical microbiology.

[107]  Regan Pj,et al.  The approach used to establish the safety of veterinary vaccines produced in the BHK 21 cell line. , 1987 .

[108]  P. Sureau.  Rabies vaccine production in animal cell cultures. , 1987, Advances in biochemical engineering/biotechnology.

[109]  A. Letsou,et al.  Homology requirement for efficient gene conversion between duplicated chromosomal sequences in mammalian cells. , 1987, Genetics.

[110]  C. Rupprecht,et al.  Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[111]  R. Lathe,et al.  Oral vaccination of the fox against rabies using a live recombinant vaccinia virus , 1986, Nature.

[112]  C. Rupprecht,et al.  Immunogenic properties of vaccinia recombinant virus expressing the rabies glycoprotein , 1985 .

[113]  R. Lathe,et al.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[114]  P. Munz,et al.  Polarity in adenovirus recombination. , 1984, Virology.

[115]  A. L. Wezel,et al.  Advances in Biotechnological Processes , 1984 .

[116]  E. Weinmann,et al.  A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests. , 1984, Journal of biological standardization.

[117]  P. Branton,et al.  Transformation by human adenoviruses , 1984, Journal of cellular physiology. Supplement.

[118]  B. Dietzschold,et al.  Rabies subunit vaccines. , 1983, The Journal of general virology.

[119]  P. Munz,et al.  The genetic analysis of adenovirus recombination in triparental and superinfection crosses. , 1983, Virology.

[120]  F Steck,et al.  Oral immunisation of foxes against rabies. A field study. , 2010, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B.

[121]  E. Paoletti,et al.  Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[122]  M. Singer,et al.  Summary statement of the Asilomar conference on recombinant DNA molecules. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[123]  Walter G Chapman,et al.  Inactivated rabies vaccine produced from the Flury LEP strain of virus grown in BHK-21 suspension cells. , 1973, Applied microbiology.

[124]  P. Atanasiu,et al.  [Antirabies vaccines from tissue culture obtained with the Pasteur strain. Results of vaccination]. , 1972, Annales de l'Institut Pasteur.

[125]  G. Baer,et al.  Oral vaccination of foxes against rabies. , 1971, American journal of epidemiology.

[126]  H. R. Cox,et al.  Studies on chick embryo adapted rabies virus; culture characteristics and pathogenicity. , 1948, Journal of immunology.